Cartesian Therapeutics (RNAC) Operating Leases (2018 - 2026)

Cartesian Therapeutics (RNAC) has reported Operating Leases for 9 consecutive years, with $7.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 45.48% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (down 45.48% YoY), while the FY2025 annual figure was $8.5 million, down 23.43% from the prior year.
• Operating Leases fell to $7.7 million in Q1 2026 per RNAC's latest filing, from $8.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $14.1 million in Q1 2025 and bottomed at $3.2 million in Q4 2022.
• Historically, Operating Leases has averaged $9.7 million across 5 years, with a median of $9.2 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Leases sank 62.78% — and 2023, when it soared 174.66%.
• Cartesian Therapeutics' Operating Leases stood at $3.2 million in 2022, then jumped by 174.66% to $8.8 million in 2023, then rose by 26.67% to $11.1 million in 2024, then decreased by 23.43% to $8.5 million in 2025, then slipped by 10.04% to $7.7 million in 2026.
• Business Quant data shows RNAC's Operating Leases at $7.7 million in Q1 2026, $8.5 million in Q4 2025, and $8.7 million in Q3 2025.